United States: A Guide to New Jersey's New Limits On Pharmaceutical Industry Payments To Prescribers

Last Updated: February 2 2018
Article by Jordan T. Cohen and Bethany J. Hills

The pharmaceutical industry is facing new limits on payments to prescribers in New Jersey. Earlier this month the state's Division of Consumer Affairs finalized sweeping new rules prohibiting some types of payments and capping others. New Jersey now joins the ranks of other states, like California and Massachusetts, with specific payment prohibitions between manufacturers and prescribers. The new rules place the burden of compliance on prescribers licensed in New Jersey, but manufacturers should be fluent in these requirements. We expect engagement and collaboration with New Jersey prescribers to be impacted, as these rules are clearly designed to be a disincentive to financial arrangements between manufacturers and prescribers. How deeply this impacts ongoing and new collaborations with prescribers is yet to be seen, as manufacturers do rely on prescribers for contributions to product design, product feasibility in clinical workflow, and patient expectations. Below is a summary of the key aspects of the new rules, along with tables to assist in identifying how certain payments are affected.

When is the Effective Date?

The regulations became effective on January 16, 2018. The restrictions do not apply to contracts entered into on or before January 15, 2018.

Who is impacted?

The regulations apply to payments from "pharmaceutical manufacturers" to "prescribers." The regulations define "pharmaceutical manufacturers" as entities, or their agents, that either:

  1. engage in the production, preparation, propagation, compounding, conversion, or processing of prescription drugs or biologics; or
  2. directly engage in the packaging, repackaging, labeling, relabeling, or distribution of prescription drugs or prescription biologics.

The rule carves out prescribers that are employees of a manufacturer, so long as the employees don't provide patient care.

The regulations define "prescribers" to include licensed physicians, podiatrists, physician assistants, advanced practice nurses, dentists, or optometrists.

What Payments are Prohibited?

The following table sets forth the payments that prescribers are prohibited from receiving from pharmaceutical manufacturers and their agents:

Prohibited Payments Details
Financial or in-kind benefits Examples include gifts, payments, stock, stock options, grants, scholarships, subsidies, and charitable contributions.
Entertainment or recreational items Examples include tickets to theater or sporting events, or leisure or vacation trips.
Items of value that do not advance disease or treatment education

This category includes:

1. Pens, note pads, clipboards, mugs, or other items with a company or product logo;

2. Items intended for the personal benefit of the prescriber or staff, such as floral arrangements, sporting equipment, artwork, or items that may have utility in both the professional and nonprofessional setting, such as electronic devices;

3. Payments in cash or cash equivalent, such as a gift certificates; and

4. Payments or direct subsidies to a non-faculty prescriber to support attendance at, or as remuneration for time spent attending, or for the costs of travel, lodging, or other personal expenses associated with attending any education event or a promotional activity.

Note: Educational events and promotional activities are subject to an exception. See discussion of exceptions, below.

Meals There is an exception for "modest meals." See discussion of exceptions below.

The restrictions apply equally to payments made to a prescriber's immediate family member unless the family member is employed by a pharmaceutical manufacturer and receives the payments as part of their usual and customary employment relationship.

What are the Exceptions?

The broad prohibition above is qualified by the following exceptions:

Exception Details
Sample medication A prescriber may accept sample medications that are intended to be used exclusively for the benefit of the prescriber's patients, as long as the prescriber follows applicable dispensing standards and doesn't charge patients for such samples.
Educational items with minimal or no value outside of professional use Examples include anatomical models, information and materials directly related to patient care or prescriber education, and electronic devices that are used by patients and remain in a common area of the prescriber's office.
Subsidized registration fees Subsidized fees at an education event if that fee is available to all event participants
Modest meals Modest meals can be provided if they have a fair market value of no more than $15 and are provided by (i) an event organizer at an education event (provided the meals facilitate the educational program to maximize prescriber learning) or (ii) a manufacturer to non-faculty prescribers through promotional activities.
Reasonable payment or remuneration for travel, lodging, and other personal expenses Prescribers can receive payments made in connection with research activities as well as payments made to prospective applicants in connection with employee recruitment.
Research Research activities are specifically not subject to the requirements for bona fide services and not subject to the annual cap, discussed below. Although not clearly drafted in the rules as an exception, payments for research activities appear to be permitted.
Royalties and licensing fees This exception is limited to royalties and licensing fees paid in return for contractual rights to use or purchase a patented or otherwise legally recognized discovery for which the prescriber holds an ownership right.
Compensation for educational events Prescribers can receive fair market value compensation for providing bona fide services as a speaker or faculty organizer or academic program consultant. In this context, prescribers can also receive reasonable payment for travel, lodging, and other personal expenses. Prescribers can be granted continuing education credits for participation in such activities.

Compensation for promotional activities

[Subject to cap. See below]

Prescribers can receive compensation, based on fair market value, for providing bona fide services as a speaker or faculty organizer or academic program consultant for a promotional activity. In this context, prescribers can also receive reasonable payment for travel, lodging, and other personal expenses. A prescriber may not claim continuing education credit for participation in such activities.

Compensation for participation on an advisory board or other consulting arrangement

[Subject to cap. See below]

Prescribers can receive compensation, based on fair market value, for participation on advisory bodies or under consulting arrangements. A prescriber serving in this capacity also may accept reasonable payment or remuneration for travel, lodging, and other personal expenses associated with such services.

What is "promotional activity"? What is "research"?

"Promotional activity" is defined as any unaccredited activity, meeting, or program organized or sponsored by a pharmaceutical manufacturer, or the manufacturer's agent, that is directed at prescribers to promote the prescription, recommendation, supply, administration, use, or consumption of the manufacturer's products through any media or medium. "Promotional activity" excludes educational events or services provided in connection with research activities.

"Research" is defined as any study assessing the safety or efficacy of prescribed products administered alone or in combination with other prescribed products or other therapies, or assessing the relative safety or efficacy of prescribed products in comparison with other prescribed products or other therapies. Research also includes systemic investigation, including scientific advising on the development, testing and evaluation that is designed to develop or contribute to general knowledge, or reasonably can be considered to be of significant interest or value to scientists or prescribers working in a particular field. "Research" includes both pre-market and post-market activities that satisfy the requirements of the above definition.

What are "bona fide services"?

The exceptions allowing for compensation for educational events and promotional activities require that the payments be for "bona fide services." The regulations define "bona fide services" as those services provided by a prescriber pursuant to an arrangement formalized in a written agreement including, but not limited to, presentations as speakers at promotional activities and education events, participation on advisory boards, and consulting arrangements. Services provided in connection with research are excluded from the definition. In what might be a drafting error, the exception dealing with advisory board and other consulting arrangements does not include a reference to "bona fide services." But given that the definition of "bona fide services" itself references these types of arrangements, we believe the requirements for "bona fide services," including the written agreement requirement and in some cases an annual cap, discussed below, should be read to apply equally to those advisory board and consulting arrangements.

How must "bona fide services" be memorialized?

The written agreement required for the bona fide services mentioned above must specify:

  1. The services to be provided;
  2. The dollar value of the consideration, which must be based on the fair market value of the services; and
  3. That the meetings held in association with bona fide services occur in venues and under circumstances conducive to the services provided and that the activities related to the services are the primary focus of the meeting.

The agreement must also identify the following:

  1. The legitimate need for services in advance;
  2. The connection between the competence, knowledge, and expertise of the prescriber and the purpose of the arrangement;
  3. How participation of the prescriber is reasonably related to achieving the identified purpose;
  4. The manner by which the prescriber will maintain records concerning the arrangement and the services provided by the prescriber; and
  5. An attestation that the prescriber's decision to render the services is not unduly influenced by a pharmaceutical manufacturer's agent.

What is the cap on compensation for "bona fide services"?

Payments received by prescribers under the exceptions for bona fide promotional and advisory/consulting services are subject to a calendar year aggregate cap of $ 10,000 that includes payments received from all pharmaceutical manufacturers. Payments for speaking at education events are not subject to the cap, but still must be for fair market value and set forth in a written agreement. Payments for research activities and payments for royalties and licensing fees are not subject to the cap.

Public Disclosure Requirement

Prescribers serving as speakers at an education event or for a promotional activity are required to directly disclose to attendees either orally or in writing at the beginning of the presentation that the prescriber accepted payment for bona fide services from the sponsoring pharmaceutical manufacturer within the preceding five years.


The rule does not provide for penalties against pharmaceutical manufacturers for violations. Instead, enforcement will rest with the prescribers' respective licensing boards which will have the authority to impose disciplinary action and/or civil penalties.

Compliance Considerations

Physicians, podiatrists, physician assistants, advanced practice nurses, dentists, and optometrists should ensure that payments they receive from pharmaceutical manufacturers fall outside the ambit of the regulation or fit with an exception. When providing bona fide services, these prescribers should consider working with counsel to ensure that a compliant agreement is executed and should have appropriate documentation on file to demonstrate that the payments received did not exceed the $10,000 annual cap. Pharmaceutical manufacturers (including packagers, repackagers, labelers, relablers, and distributors) should revise their policies and procedures to provide compliant arrangements with prescribers on a going forward basis.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions